http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110988196-B

Outgoing Links

Predicate Object
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2030-324
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-32
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-34
filingDate 2019-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2022-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2022-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-110988196-B
titleOfInvention Analysis method of gentamicin B content
abstract The invention discloses a method for analyzing the content of gentamicin B, which comprises the following steps: determining by reversed-phase liquid chromatography, selecting a C18 chromatographic column as a chromatographic column, and a mobile phase consisting of water, a buffer solution and an organic solvent, which are set according to volume fractions, etc. and quantitative analysis by external standard method. The liquid chromatography conditions are as follows: octadecylsilane bonded silica gel is used as the packing material, the specification is 250*4.6mm, 5μ or its equivalent chromatographic column, and the concentration of the buffer salt in the mobile phase is 0.01 to 0.03mol/L , phosphoric acid to adjust its pH to 4.0 to 6.0, the volume ratio of buffer to organic solvent in the mobile phase is 4:1 to 21:4, the detection wavelength is 325nm to 335nm, the column temperature is 30 to 40°C, and the flow rate is 0.8 to 1.2ml/min. The chromatographic condition analysis method is practical and reliable, has good stability and high sensitivity, and is convenient for the determination of gentamicin B content.
priorityDate 2019-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415783739
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449122806
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11754987
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411550722
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID516951
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87730
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6342
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24261
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457707758
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1004
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559502
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426283030
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635

Total number of triples: 31.